Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome

Fabián Pitoia1, Fernanda Bueno1, Angélica Schmidt1, Sabrina Lucas1, Graciela Cross1

SUMMARY

Medullary thyroid carcinoma (MTC) may rarely present with paraneoplastic syndromes. Among the most frequent ones are the appearance of diarrhea and ectopic Cushing syndrome (ECS). The ECS in the context of MTC is usually present in patients with distant metastatic disease. The use of drugs such as ketoconazole, metyrapone, somatostatin analogs and etomidate have been ineffective alternatives to control hypercortisolism in these patients. Bilateral adrenalectomy is often required to manage this situation. Recently, the use of tyrosine kinase inhibitors has been shown to be a useful tool to achieve eucortisolism in patients with metastatic MTC and ECS. We present a patient with sporadic advanced persistent and progressive MTC with lymph node and liver metastases, which after 16 years of follow-up developed an ECS. After one month of 300 mg/day vandetanib treatment, a biochemical and clinical response of the ECS was achieved but it did not result in significant reduction of tumor burden. However the patient reached criteria for stable disease according to response evaluation criteria in solid tumors (RECIST 1.1) after 8 months of follow-up. Arch Endocrinol Metab. 2015;59(4):343-6

Keywords
Vandetanib; medullary thyroid cancer; ectopic Cushing syndrome

INTRODUCTION

Medullary thyroid carcinoma (MTC) accounts for less than 5% of all thyroid cancers. It arises from parafollicular or C cells, which are derived from embryological neural crest. Around 75% of MTC are sporadic and the rest of them are hereditary with an autosomal dominant pattern and a penetrance of up to 100%. These cases are associated with mutations in the RET proto-oncogene in the context of what is known as multiple endocrine neoplasia (MEN): MEN 2A, 2B and familial MTC (1,2).

The 10-year survival rate for patients with sporadic MTC is 96% if the disease is treated while the tumor is confined to the thyroid gland (3). However, distant metastases are observed at presentation in nearly 20% of patients (1). Of these, about 40% will die of the disease within 2 years after the diagnosis (3).

MTC produces specific serum markers, such as calcitonin. Furthermore, it can also secrete substances such as carcinoembryonic antigen (CEA), and less frequently, other peptides such as serotonin, substance P, vasoactive intestinal peptide, adrenocorticotropic hormone (ACTH), corticotropin releasing hormone (CRH), catecholamine metabolites and histamine and calcitonin related peptide (4). The main complications that can occur as a consequence of the hypersecretion of these substances usually is diarrhea. On the other hand, the over secretion of ACTH or CRH may determine the appearance of ectopic Cushing syndrome (ECS) (1). The ECS may occur from the moment of the diagnosis of the MTC until more than 2 decades later (5-10). However, the ECS is a rare complication in patients with MTC. To our knowledge, only 50 cases of ECS secondary to MTC have been described in the literature (6). In general, these patients do not respond to conventional anti-cortisol treatments, and generally have a high mortality (6). Moreover, fifty percent of them will die from complications arising from severe hypercortisolism and only 20% survive longer than one year after the diagnosis of ECS (6).

Vandetanib is a once-daily oral tyrosine-kinase inhibitor which selectively targets the rearranged during transfection (RET) receptor, the epidermal growth factor receptor (EGFR), and also the vascular endothelium...
growth factor receptor (VEGFR) (11,12). Vandetanib (Caprelsa®, ZD6474; AstraZeneca) is the first drug approved for the treatment of symptomatic and/or progressive MTC in patients with unresectable, locally advanced, or metastatic disease in the United States, Europe and also, in a number of countries around the world, which includes Argentina and Brazil. The study that led to this approval was the ZETA trial which showed a significant longer median progression-free survival (PFS) vs. placebo (30.5 vs. 19.3 months; p = 0.001) in this setting, (HR 0.46; 95% CI 0.31 to 0.69; p < 0.001) with an estimated 11-month prolongation of median PFS (10). Vandetanib also demonstrated significantly higher rates of objective response (45% vs. 13% for placebo; p < 0.001), and calcitonin biochemical response (69% vs. 3% for placebo; p < 0.001) (13).

The aim of this publication is to present a case of advanced MTC who developed an ECS that rapidly responded to vandetanib 300 mg/day treatment, with a stabilization of disease progression of the MTC during follow-up. The patient provided written consent for the publication of this case report.

CASE REPORT

A 37 year-old woman with a diagnosis of sporadic MTC has been followed-up at our institution during all the course of her disease.

Sixteen years ago, a fine needle aspiration of a 13 mm diameter thyroid nodule yielded a diagnosis of MTC. She underwent a total thyroidectomy together with a right cervical neck dissection. Due to local and lymph node structural persistence, five subsequent surgeries were required: bilateral neck dissection, mediastinal lymph node dissection, resection of a right paratracheal local recurrence and, finally, removal of mediastinal nodes and a left supraclavicular lymphadenopathy. This last surgery was performed 2 years ago.

She sought medical attention for evaluation of as-thenia, dry cough and functional class III dyspnea. Physical examination revealed hypertension (150/100 mmHg), tachycardia (110 beats per minute), full moon facies, plethora, dorsal hump, asymmetry and marked collateral circulation in the left cervical and axillary level by the presence of edema. She also showed a 10 cm diameter hard-stone consistency, supraclavicular left mass.

The biochemical analysis showed calcitonin levels of 4200 pg/mL (NV < 5 pg/mL), CEA 35 ng/mL (NV < 4.6 ng/mL) elevated plasma ACTH (49 pg/mL, NV < 46 pg/mL), 24 hs urinary free cortisol (UFC) elevated in two occasions (400 and 600 pg/24 h, NV 20-200 ug/24 hs), lack of suppression with 1 and 8 mg dexamethasone (Serum cortisol of 22 ug/dL and 23 ug/dL, respectively, with a basal value of serum cortisol of 19 ug/dL), and loss of normal circadian rhythm (22-23 hs UFC 45 ng/mg creatinine, NV < 30 ng/mg creatinine). The MRI of the sellar region showed no abnormalities in the pituitary gland. A CT of the chest, abdomen and pelvis showed multiple enlarged lymph nodes in the left cervical and mediastinal region with diameters between 18-50 mm, and multiple hypervascular focal liver lesions between 15 to 33 mm in diameter (Figure 1).

![Image](A) 49.1 mm (2D) 17.9 mm

**Figure 1.** Computed tomography of the chest (A) showing multiple enlarged lymph nodes in the mediastinal region and nuclear magnetic resonance of the abdomen (B) demonstrating hypervascular hepatic lesions (white arrows) in a patient with ectopic Cushing syndrome due to metastatic medullary thyroid cancer.
Due to metastatic, progressive and symptomatic MTC, we decided to start vandetanib 300 mg/day oral treatment. As an adverse event to the drug, the patient presented a generalized grade 1 skin rash that occurred three weeks after vandetanib initiation. The rash resolved spontaneously under vandetanib 300 mg/day treatment. Other laboratory assessments and ECG, including measurement of QT interval, were always normal.

One month after treatment initiation, the patient showed clinical response (normalization of blood pressure, decreased edema and decreased collateral circulation in the left chest and also, improvement of fatigue) and biochemical improvement (UFC: 68 ug/24 hs, calcitonin 1100 pg/mL). These clinical and biochemical responses were kept until the time of this publication (8 months) (Figure 2).

Despite this improvement, imaging studies performed to evaluate tumor response showed no significant changes in the size of the metastatic lesions of the MTC. Currently, the patient maintains the benefits achieved with vandetanib treatment at full dosage.

DISCUSSION

The ECS is caused by the secretion of extra-pituitary ACTH or CRH, and represents 9 to 18% of cases of Cushing Syndrome (14). The most common causes of ECS are bronchial carcinoid and small cells lung cancer and infrequently, in 2 to 7.5% of cases, MTC (14).

Immunohistochemical analyses have shown that up to 40% of MTC usually secret ACTH (15). However, it is only clinically evident in 0.6% of cases and it generally occurs in patients with advanced metastatic disease (6). ECS related to MTC diagnosis is based on the presence of hypercortisolism (with elevated or inappropriately normal ACTH) that is not suppressed by the 8 mg dexamethasone test, absence of pituitary adenoma in MRI, and parallel progression of the Cushing Syndrome together with the MTC metastatic spread (6).

The treatment of these patients usually involves the use of drugs such as ketoconazole, metyrapone, somatostatin analogs and etomidate. All of these agents have low effectiveness in controlling hypercortisolism. As a consequence, bilateral adrenalectomy is frequently required to control this situation (6).

Recently, four cases of ECS associated to MTC with rapid response to tyrosine kinase inhibitors have been published: to sunitinib (16), sorafenib (17) and vandetanib treatments (18,19) (Table 1).

Vandetanib inhibits tyrosine kinase activity of the RET receptor, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor-2 (VEGFR), and has been proven effective in patients with and without mutations of the oncogene (20). Since its approval in 2011 by the Food and Drug Administration in the United States and in 2013 by the ANMAT (the health agency from Argentina), 2 case reports of successful treatment with vandetanib for ECS control in patients with advanced MTC have been published. In both cases there were no decrease in the size of the tumor mass (18,19).

Figure 2. Changes in serum calcitonin and urinary free cortisol levels at the time of diagnosis and their outcome after vandetanib 300 mg/day oral treatment in a patient with ectopic Cushing syndrome due to a metastatic medullary thyroid carcinoma.
In our patient, the hypercortisolism responded rapidly to vandetanib treatment (only one month). In addition, structural stability of the MTC was observed eight months after the prescription of the drug. This is coincident with the two previously described cases, suggesting the hypothesis that this kind of drugs would have a direct effect by blocking CRH or ACTH secretion by the tumor cells. This situation would be independent of their antiproliferative effect (18).

Therefore, we confirm previous findings showing that the treatment with vandetanib quickly and effectively controlled the ectopic ACTH/CRH secretion in this patient with advanced MTC. Additional studies are necessary to assess the impact on its use in other ECS etiologies.

Disclosure: Fabián Pitoia is a consultant and speaker bureau for AstraZeneca in Argentina. The remaining authors have nothing to declare.

REFERENCES


Table 1. Published case reports in the literature of ectopic Cushing syndrome (ECS) due to medullary thyroid cancer who received tyrosine kinase inhibitors (TKI) treatment (the type of TKI, response of the ECS and the tumoral response are presented)

<table>
<thead>
<tr>
<th>Case report</th>
<th>MTC type</th>
<th>Treatment (drug/dosage)</th>
<th>Treatment duration (months)</th>
<th>Response of hypercortisolism (days)</th>
<th>Tumoral response</th>
<th>Treatment withdrawal/under treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baudry and cols. (Ref. 18)</td>
<td>NR</td>
<td>Vandetanib 300 mg/d</td>
<td>4.2</td>
<td>15</td>
<td>SD</td>
<td>NR</td>
</tr>
<tr>
<td>Nella and cols. (Ref. 19)</td>
<td>MEN 2B</td>
<td>Vandetanib 200 mg/d</td>
<td>29</td>
<td>30</td>
<td>SD</td>
<td>Tumoral progression</td>
</tr>
<tr>
<td>Barroso-Sousa and cols. (Ref. 17)</td>
<td>Sporadic</td>
<td>Sorafenib 800 mg/d</td>
<td>15</td>
<td>7</td>
<td>SD</td>
<td>Tumoral progression and ESC recurrence</td>
</tr>
<tr>
<td>Marques and cols. (Ref. 16)</td>
<td>Sporadic</td>
<td>Sunitinib 25 mg/d + Metilapone</td>
<td>5</td>
<td>NR</td>
<td>PR</td>
<td>Continues under treatment</td>
</tr>
</tbody>
</table>

Ref.: reference number; NR: not reported; MEN 2B: multiple endocrine neoplasia 2B; SD (stable disease); PR (partial response).